BRAF and melanoma: The effectiveness of this approach was demonstrated in a phase 3 clinical trial involving patients who had underwent resection of a stage III BRAF V600E or V600K-positive melanoma followed by 12-month adjuvant therapy (dabrafenib + trametinib).